Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie.
Gencer D, Tauchert F, Keilhauer N, Al-Batran SE, Stahl M, Oskay-Özcelik G, Hipp M, Leibbrand B, Prasnikar N, Trarbach T, Stoll C, van Kampen M, Hochhaus A, Lorenzen S, Hofheinz RD. Gencer D, et al. Onkologie. 2011;34(8-9):435-40. doi: 10.1159/000330940. Epub 2011 Aug 19. Onkologie. 2011. PMID: 21934343
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Hofheinz RD, et al. Among authors: gencer d. Lancet Oncol. 2012 Jun;13(6):579-88. doi: 10.1016/S1470-2045(12)70116-X. Epub 2012 Apr 13. Lancet Oncol. 2012. PMID: 22503032 Clinical Trial.
Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval.
Gencer D, Al-Batran SE, Dada R, Hünerlitürkoglu AN, Gonnermann M, Kegel T, Scheiber H, Jordan WO, Burkholder I, Kellermann L, Hofheinz RD. Gencer D, et al. J Cancer Res Clin Oncol. 2013 Feb;139(2):337-45. doi: 10.1007/s00432-012-1335-7. Epub 2012 Oct 19. J Cancer Res Clin Oncol. 2013. PMID: 23080134
32 results